Free Trial
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Price, News & Analysis

$23.16
-0.11 (-0.47%)
(As of 05/24/2024 ET)
Today's Range
$22.96
$23.51
50-Day Range
$17.98
$25.47
52-Week Range
$13.82
$25.95
Volume
365,955 shs
Average Volume
977,203 shs
Market Capitalization
$2.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.57

Myriad Genetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
10.4% Upside
$25.57 Price Target
Short Interest
Bearish
6.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.59mentions of Myriad Genetics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$3.49 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.35) to ($0.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

388th out of 923 stocks

Diagnostic Substances Industry

6th out of 13 stocks

MYGN stock logo

About Myriad Genetics Stock (NASDAQ:MYGN)

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

MYGN Stock Price History

MYGN Stock News Headlines

MYGN Aug 2024 33.000 call
MYGN Jun 2024 22.000 put
Myriad Genetics Inc. Q1 Loss Decreases, beats estimates
Myriad Genetics earnings preview: what Wall Street is expecting
Myriad Genetics Q1 2024 Earnings Preview
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/25/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,700
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$25.57
High Stock Price Target
$35.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+10.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-263,300,000.00
Pretax Margin
-30.42%

Debt

Sales & Book Value

Annual Sales
$753.20 million
Book Value
$8.40 per share

Miscellaneous

Free Float
88,607,000
Market Cap
$2.10 billion
Optionable
Optionable
Beta
1.96

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Paul J. Diaz (Age 62)
    CEO, President & Director
    Comp: $2.31M
  • Mr. Samraat S. Raha (Age 51)
    Chief Operating Officer
    Comp: $514.76k
  • Dr. Dale Muzzey Ph.D. (Age 44)
    Chief Scientific Officer
    Comp: $816.5k
  • Mr. Mark S. Verratti (Age 56)
    Chief Commercial Officer
    Comp: $915.81k
  • Mr. Scott J. Leffler (Age 49)
    Chief Financial Officer
  • Ms. Natalie Munk (Age 43)
    Principal Accounting Officer
  • Dr. Kevin Richard Haas Ph.D. (Age 38)
    Chief Technology Officer
    Comp: $580.36k
  • Mr. Matthew Scalo
    Senior Vice President of Investor Relations
  • Mr. Glenn Farrell
    Senior VP & Chief Marketing Officer
  • Ms. Shereen Solaiman (Age 51)
    Chief People Officer

MYGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MYGN shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price target for 2024?

8 equities research analysts have issued twelve-month target prices for Myriad Genetics' shares. Their MYGN share price targets range from $14.00 to $35.00. On average, they predict the company's stock price to reach $25.57 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2024?

Myriad Genetics' stock was trading at $19.14 on January 1st, 2024. Since then, MYGN shares have increased by 21.0% and is now trading at $23.16.
View the best growth stocks for 2024 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.09. The business earned $202.20 million during the quarter, compared to the consensus estimate of $193.51 million. Myriad Genetics had a negative net margin of 30.30% and a negative trailing twelve-month return on equity of 6.77%. The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) EPS.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 0.000-0.050 for the period, compared to the consensus estimate of 0.020. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $826.6 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.09%), Earnest Partners LLC (4.35%), Sei Investments Co. (2.53%), Principal Financial Group Inc. (0.52%), Mirae Asset Global Investments Co. Ltd. (0.37%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Lee Nisley Newcomer, Nicole Lambert, Paul J Diaz, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends
.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
This page (NASDAQ:MYGN) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners